Mammographic changes in women receiving tibolone therapy

Fertility and Sterility

Volumn 69, Issue 5, 1998, Pages 870-875

  Erel, Cemal Tamer ^a,b   Elter, Koray ^b   Akman, Canan ^b   Ersavasti, Gul ^b   Altug, Ayca ^b   Seyisoglu, Hakan ^b   Ertungealp, Erdogan ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE

Author keywords

Breast cancer; DHEAS; HRT; Mammographic changes; Tibolone

Indexed keywords

ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PRASTERONE; PROLACTIN; TESTOSTERONE; TIBOLONE;

ADULT; ARTICLE; BREAST CALCIFICATION; BREAST CANCER; CANCER RISK; CANCER SCREENING; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBROCYSTIC BREAST DISEASE; FOLLOW UP; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAMMOGRAPHY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL;

DEHYDROEPIANDROSTERONE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; NORPREGNENES; PROSPECTIVE STUDIES;

EID: 0032080247     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00051-X     Document Type: Article

References (33)

1. 1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. 2. Kelsey JL. A review of the epidemiology of human breast cancer. Epidemiol Rev 1979;1:74-109.
3. 3. Moore DH, Moore DH II, Moore CT. Breast carcinoma etiologic factors. Adv Cancer Res 1983;40:189-253.
4. 4. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-43.
5. 5. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
6. 6. Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer C. Combined oestrogen-progestogen replacement and breast cancer risk. Lancet 1992;340:1044.
7. 7. Colditz GA, Hankinson SE, Hunter DJ, Willet WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332: 1589-93.
8. 8. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc 1995;274:137-42.
9. 9. Costanza ME. Breast cancer screening in older women: synopsis of a forum. Cancer 1992;69:1925-31.
10. 10. Tabar L, Fagerberg CJG, Gad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomized trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1:829-32.
11. 11. Kopans DB. Screening for breast cancer and mortality reduction among women 40-49 years of age. Cancer 1994;74:311-22.
12. 12. Wolfe JN. Breast parenchymal patterns and their changes with age. Radiology. 1976;121:545-52.
13. 13. Sickles EA, Ominsky SH, Sollitto RA, Galvin HB, Monticciolo DL. Medical audit of a rapid-throughput mammography screening practice: methodology and results of 27.114 examinations. Radiology 1990;175: 323-7.
14. 14. Stomper PC, VonVoorkis BJ, Ravnikar VA, Meyer JE. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990;174:487-90.
15. 15. Berkowitz JE, Gatewood OMB, Goldblum LE, Gayler BW. Hormonal replacement therapy: mammographic manifestations. Radiology 1990; 174:199-201.
16. 16. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196: 433-7.
17. 17. Erel CT, Seyisoglu H, Senturk ML, Akman C, Ersavasti G, Benian A, et al. Mammographic changes in women on hormonal replacement therapy. Maturitas 1996;25:51-7.
18. 18. Tax L. Hormone replacement therapy. Livial (Org OD14), a new possibility. In: Schonbaum E, editor. Progress in basic and clinical pharmacology. Basel: S. Karger, 1991:143-59.
19. 19. Trevoux R, Dieulangard P, Blum A. Efficacy and safety of Ogr OD14 in the treatment of climacteric complaints. Maturitas 1983;5:89-96.
20. 20. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419-22.
21. 21. Ertungealp E, Erel CT, Seyisoglu H, Colgar U. Effect of tibolone on bone mineral density and endometrial thickness. 1996 World Congress on Osteoporosis. Amsterdam. Osteoporos Int 1996;6(Suppl 1):231.
22. 22. Genazzani AR, Benedek JLJ, Hart DM, Andolsek L, Kicovic PM, Tax L. Org OD14 and the endometrium. Maturitas 1991;13:243-51.
23. 23. Wolfe JN. Breast patterns as an index of risks for developing cancer. AJR Am J Roentgenol 1976;126:1130-9.
24. 24. Wolfe JN. Risk of breast cancer development determined by mammographic parenchymal pattern. Cancer 1976;37:2486-93.
25. 25. McNicholas MMJ, Heneghan JP, Milner MA, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR Am J Roentgenol 1994;163:311-5.
26. 26. Gingsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial) over 8 years. Maturitas 1995;21:71-6.
27. 27. O'Brien MER, Montes A, Powles TJ. Hormone replacement therapy as treatment of breast cancer - a phase II study of Org OD14 (tibilone). Br J Cancer 1996;73:1086-8.
28. 28. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Res 1976;36:4595-601.
29. 29. Aitken SC, Lippman ME. Effects of estrogens and antiestrogens on growth regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res 1985;45:1611-20.
30. 30. Kloosterboer HJ, Schoonen WGEJ, Deckers GH, Klijn JGM. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994;49:311-8.
31. 31. Dauvois S, Li S, Martel C, Labrie F. Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat. Breast Cancer Res Treat 1989;14:299-306.
32. 32. Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW, Fukushima DK. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res 1981;41:3360-3.
33. 33. Ebeling P, Kolvisto VA. Physiological importance of dehydroepiandrosterone. Lancet 1994;343:1479-81.